New treatments see blood cancer survival rates up

The formula above is not meant as a math trick.  But it does depict some tricky math for cancer survivors like me.

All that I have to say about this search and this topic is that it is good to be counted among the one in four.  That is, according to this source, one in four NHL (non-Hodgkin’s lymphoma) survivors have a chance of surviving for five years.   Count me at 5.8 years since my stem cell transplant and 7 years since the diagnosis of mantle cell lymphoma (MCL), a potent form of NHL.

Reading this article and seeing this illustration of the three bags of stem cells makes for a personal flashback to the August 2007 SCT procedure at City of Hope.

MYJ ZONE (My Journal)
publisher for
constant web and mobile communication
___
http://altacities.com  The alternate blogs ~ Productions by #ALTALOMAN
When you change the way you look at things, the things you look at change
___
Now a member of SCAGA }:{  alt@cities on paper.li 

 

Advertisements

Human Embryonic Stem Cells Derived by Somatic Cell Nuclear Transfer

Human Embryonic Stem Cells Derived by Somatic Cell Nuclear Transfer }:{ My August 2007 stem cell transplant (SCT) was done with adult cells from an unrelated donor.  While the procedure is fraught with risks, mortality, and morbidity factors for the recipient, an SCT or the BMT (bone marrow) equivalent is virtually harmless to the adult donor.
 }:{  alt@search  }:{  alt@story   }:{ 

Because I was the recipient of life-saving stem cells 5.8 years ago, I am naturally more than a casual observer of the science.  But everyone who seriously follows this story line and these tweets, realizes that society and medicine at large both face certain ethical questions regarding transplants using embryonic cells.  While the adult cells issue is largely resolved, I am not sure that this “breakthrough” cloning of embryonic cells solves the larger ethical issue, but it does bring the science to an important threshold, thanks to the work of:

Shoukhrat Mitalipov is an associate scientist in the Division of Reproductive & Developmental Sciences of ONPRC, Oregon Stem Cell Center and Departments of Obstetrics & Gynecology and Molecular & Medical Genetics, and co-director of the ART/ESC core at the Center. He earned his Ph.D. degree in Developmental & Stem Cell Biology at the Research Center for Medical Genetics in Moscow, Russia. He came to Utah State University in 1995 to conduct his postdoctoral research in stem cell and developmental biology. Dr. Mitalipov moved to the Oregon center in 1998.

In summary, the research by Dr. Mitalipov deals with totipotent and pluripotent stem cells that are important as a unique research tool that allows investigation of the mechanisms regulating early primate development and differentiation. Human stem cells also provide the far-reaching foundation for the field of regenerative medicine and offer hope for the treatment of a wide range of clinical conditions that can be attributed to the loss or malfunction of specific cell types. Translational research in the clinically relevant nonhuman primate model is highly desirable to evaluate the safety, feasibility and efficacy of cell-based therapies. The basic research conducted in the Mitalipov lab provides new insights into the generation, maintenance and developmental potential of primate totipotent and pluripotent stem cells.

and publisher of alt@cities on paper.li for
constant web and mobile communication
___
http://altacities.com  The alternate blogs ~ Productions by #ALTALOMAN
When you change the way you look at things, the things you look at change
___
Now a member of SCAGA